Author name: YARAL Pharma

The TRANSAT CIC Started Yesterday: Alberto Bona And The Class40 IBSA In Fourth Position After 24 Hours Of Navigation

THE TRANSAT CIC STARTED YESTERDAY: ALBERTO BONA AND THE CLASS40 IBSA IN FOURTH POSITION AFTER 24 HOURS OF NAVIGATION PARSIPPANY, N.J. (April 29, 2024) – It was a spectacular start, on Sunday, April 28, at 1:30 p.m. for the transoceanic regatta Transat CIC, one of the most demanding tests for solo sailors, who are called

The TRANSAT CIC Started Yesterday: Alberto Bona And The Class40 IBSA In Fourth Position After 24 Hours Of Navigation Read More »

YARAL Pharma Inc logo

YARAL Pharma Marks Its First Anniversary

FOR IMMEDIATE RELEASE Media Contact: Daina Basile Kovak-Likly Communications203-762-8833, dbasile@klcpr.com YARAL PHARMA Marks Its First Anniversary Quality Products, Innovative Technology, and Exceptional Customer Service Characterize a Successful Inaugural Year Parsippany, N.J., January 9, 2024 — YARAL Pharma Inc., (YARAL Pharma) is proud to celebrate the first anniversary of its entry into the United States generics

YARAL Pharma Marks Its First Anniversary Read More »

 YARAL PHARMA LAUNCHES LIDOCAINE PATCH 5% 

FOR IMMEDIATE RELEASE CONTACT: Daina Basile Kovak-Likly Communications203-762-8833, dbasile@klcpr.com  YARAL PHARMA LAUNCHES LIDOCAINE PATCH 5%  Expands its Line of Non-Opioid Prescription Medications  PARSIPPANY, NJ – September 1, 2023 – Yaral Pharma Inc., (Yaral Pharma), the United States generics subsidiary of IBSA (Institut Biochimique SA), one of the world’s leaders in transdermal and topical patch technology,

 YARAL PHARMA LAUNCHES LIDOCAINE PATCH 5%  Read More »

YARAL Pharma partners with EVERSANA® to support the commercialization of its expanding generics portfolio

FOR IMMEDIATE RELEASE CONTACT: Daina Basile Kovak-Likly Communications203-762-8833, dbasile@klcpr.com YARAL PHARMA PARTNERS WITH EVERSANA TO SUPPORT THE COMMERCIALIZATION OF ITS EXPANDING GENERICS PORTFOLIO Partnership Supports Commitment to Providing High-Quality Products, Supply Chain Continuity, and Exceptional Customer Service PARSIPPANY, NJ – May 22, 2023 – YARAL Pharma Inc., (YARAL Pharma) the United States generics subsidiary of

YARAL Pharma partners with EVERSANA® to support the commercialization of its expanding generics portfolio Read More »

YARAL Pharma Launches Diclofenac Epolamine Topical System 1.3%

FOR IMMEDIATE RELEASE CONTACT: Daina Basile Kovak-Likly Communications203-762-8833, dbasile@klcpr.com YARAL PHARMA LAUNCHES DICLOFENAC EPOLAMINE TOPICAL SYSTEM 1.3% Authorized Generic of Flector® Now Available Parsippany, NJ – January 3, 2023 – YARAL Pharma Inc., the US generics subsidiary of IBSA, a long-standing, multinational pharmaceutical company headquartered in Lugano, Switzerland today announced the launch of diclofenac epolamine

YARAL Pharma Launches Diclofenac Epolamine Topical System 1.3% Read More »

Scroll to Top